Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant

Sep 12, 2016

Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference

Sep 6, 2016

UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results

Aug 12, 2016

Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results

Aug 11, 2016

Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance

Aug 8, 2016

Cellectar Biosciences Announces $2 Million NCI SBIR Contract for a Phase 2 Clinical Study

Aug 3, 2016

Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations

Jul 20, 2016

Cellectar Biosciences Announces Results of NCI-Sponsored Study of CLR 125 Showing Potential Effect Against Triple Negative Breast Cancer

Jun 23, 2016

Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in Tumor Targeting to Free Paclitaxel

Jun 15, 2016

Cellectar Biosciences Announces USPTO Issues Patent for its Radiotherapeutic PDC Portfolio, Further Strengthening and Expanding Protection for Its Delivery Platform

May 31, 2016